Citations

Clear

30 citation(s) found for "Saw, J".

Immune‐mediated neuromuscular complications of graft‐versus‐host disease
Saw, Jacqui‐Lyn , Mauermann, Michelle L. , Naddaf, Elie , Naddaf, Elie , Mauermann, Michelle L , Sidiqi, M Hasib , Alkhateeb, Hassan B.

Mayo Clinic

Muscle & Nerve | March 2, 2021 | Volume: 63 | Issue: 6 | Pages: 852-860

10.1002/mus.27214 | PMID 33651380 Get It

AbstractIntroduction/AimsWe aimed to describe the clinical phenotype, histopathological findings and overall survival (OS) of the immune‐mediated neuromuscular complications of graft‐versus‐host disease (GVHD).MethodsWe conducted a retrospective chart review of adult patients presenting with immune‐mediated neuromuscular complications of GVHD to Mayo Clinic, between April 2013 and July 2018.We collected clinical and laboratory characteristics, histopathological findings, response to treatment and survival data.ResultsWe identified 20 patients with a mean age at presentation of 55 y. Mean time from transplant to neurological presentation was 14 mo. Myositis was the most common complication seen in 17 patients, manifesting with predominantly axial and/or proximal weakness. Eleven patients had a muscle biopsy showing diffuse perimysial, predominantly macrophagic infiltration in 10, 3 of them with perimysial perivascular lymphocytic collections, and endomysial and perimysial lymphocytic infiltration in 1. Only two patients had a neuropathic complication: one each with acute inflammatory demyelinating polyradiculoneuropathy and neuralgic amyotrophy. A single patient had a myasthenic syndrome presenting with fluctuating foot drop. Nineteen patients were treated and all responded to immunosuppressive agents; however, 11 had further GVHD flares requiring escalation of therapy. After a median follow‐up of 83 mo, seven (35%) patients died: five from progressive GVHD and two from infections. The 5‐y OS from time of transplant was 68%.DiscussionMyositis is the most common immune‐mediated neuromuscular complication of GVHD while peripheral neuropathy and myasthenic syndromes appear less common. The macrophage‐predominant infiltration on muscle biopsy deserves further study to better clarify the role of macrophages in GVHD pathogenesis.
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Angiolillo, Dominick J. , Bhatt, Deepak L. , Cannon, Christopher P. , Goodman, Shaun G. , Granger, Christopher B. , Holmes, David R. , Lópes, Renato D. , Mehran, Roxana , Moliterno, David J. , Saw, Jacqueline , Tanguay, Jean-François, Faxon, David P., Mehran, Roxana , Lopes, Renato D , Bhatt, Deepak L , Angiolillo, Dominick J , Goodman, Shaun G , Granger, Christopher B , Eikelboom, John W. , Gibson, C. Michael , Price, Matthew J. , Tanguay, Jean‐François

Mayo Clinic

Circulation | February 8, 2021 | Volume: 143 | Issue: 6 | Pages: 583-596

10.1161/circulationaha.120.050438 | PMID 33555916 Get It

A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing PCI require oral anticoagulation for the prevention of cardiac thromboembolism and dual antiplatelet therapy for the prevention of coronary thrombotic complications. The combination of oral anticoagulation and dual antiplatelet therapy substantially increases the risk of bleeding. Over the last decade, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention have been reported. Since the last update in 2018, several pivotal clinical trials in the field have been published. This document provides a focused updated of the 2018 recommendations. The group recommends that in patients with atrial fibrillation undergoing PCI, a non–vitamin K antagonist oral anticoagulant is the oral anticoagulation of choice. Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor should be given to all patients during the peri-PCI period (during inpatient stay, until time of discharge, up to 1 week after PCI, at the discretion of the treating physician), after which the default strategy is to stop aspirin and continue treatment with a P2Y 12 inhibitor, preferably clopidogrel, in combination with a non–vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone.
In Vivo Entombment of Bacteria and Fungi during Calcium Oxalate, Brushite, and Struvite Urolithiasis
Saw, Jessica J. , Wilson, Elena , Dong, Yiran, Fields, Christopher J. , Merkel, Annette, Bruce, William J. , Weber, Joseph R. , Krambeck, Amy E. , Rivera, Marcelino , Large, Timothy, Lange, Dirk , Bhattacharjee, Ananda S. , Romero, Michael F. , Fouke, Bruce W. , Chia, Nicholas , Fouke, Bruce W , Saw, J J , Wilson, Elena M , Romero, Michael F , Sivaguru, Mayandi , Sanford, Robert A. , Cregger, Melissa A. , Lieske, John C. , Chia, Nicholas

Mayo Clinic

Kidney360 | December 23, 2020 | Volume: 2 | Issue: 2 | Pages: 298-311

10.34067/kid.0006942020 | PMID 35373025 Get It

Background Human kidney stones form via repeated events of mineral precipitation, partial dissolution, and reprecipitation, which are directly analogous to similar processes in other natural and manmade environments, where resident microbiomes strongly influence biomineralization. High-resolution microscopy and high-fidelity metagenomic (microscopy-to-omics) analyses, applicable to all forms of biomineralization, have been applied to assemble definitive evidence of in vivo microbiome entombment during urolithiasis. Methods Stone fragments were collected from a randomly chosen cohort of 20 patients using standard percutaneous nephrolithotomy (PCNL). Fourier transform infrared (FTIR) spectroscopy indicated that 18 of these patients were calcium oxalate (CaOx) stone formers, whereas one patient formed each formed brushite and struvite stones. This apportionment is consistent with global stone mineralogy distributions. Stone fragments from seven of these 20 patients (five CaOx, one brushite, and one struvite) were thin sectioned and analyzed using brightfield (BF), polarization (POL), confocal, super-resolution autofluorescence (SRAF), and Raman techniques. DNA from remaining fragments, grouped according to each of the 20 patients, were analyzed with amplicon sequencing of 16S rRNA gene sequences (V1–V3, V3–V5) and internal transcribed spacer (ITS1, ITS2) regions. Results Bulk-entombed DNA was sequenced from stone fragments in 11 of the 18 patients who formed CaOx stones, and the patients who formed brushite and struvite stones. These analyses confirmed the presence of an entombed low-diversity community of bacteria and fungi, including Actinobacteria, Bacteroidetes, Firmicutes , Proteobacteria , and Aspergillus niger . Bacterial cells approximately 1 μm in diameter were also optically observed to be entombed and well preserved in amorphous hydroxyapatite spherules and fans of needle-like crystals of brushite and struvite. Conclusions These results indicate a microbiome is entombed during in vivo CaOx stone formation. Similar processes are implied for brushite and struvite stones. This evidence lays the groundwork for future in vitro and in vivo experimentation to determine how the microbiome may actively and/or passively influence kidney stone biomineralization.
A brief bedside visual art intervention decreases anxiety and improves pain and mood in patients with haematologic malignancies
Saw, Jessica J. , Curry, Elizabeth A., Ehlers, Shawna L. , Scanlon, Paul D., Bauer, Brent A. , Rian, Johanna , Wolanskyj, Alexandra P. , Saw, J J , Wolanskyj-Spinner, Alexandra P , Larson, Dirk R.

Mayo Clinic

European Journal of Cancer Care | April 18, 2018 | Volume: 27 | Issue: 4 | Pages: e12852

10.1111/ecc.12852 | PMID 29667288 Get It

Head Tilt Due to Null-Point See-Saw Nystagmus
Armitage, M. Diane, Rosen, Carl E., Younge, Brian R., Arnold, Robert W.

Mayo Clinic

American Orthoptic Journal | April 6, 2018 | Volume: 46 | Issue: 1 | Pages: 181-184

10.1080/0065955x.1996.11982091 Get It

Effects of hemin on heme oxygenase‐1, gastric emptying, and symptoms in diabetic gastroparesis
Bharucha, Adil E. , Daley, Sarah, Low, Phillip A. , Choi, Kukbin , Camilleri, Michael , Saw, Jessica J. , Farrugia, Gianrico , Zinsmeister, Alan R., Gibbons, Simon J. , Saw, J J

Mayo Clinic

Neurogastroenterology & Motility | June 9, 2016 | Volume: 28 | Issue: 11 | Pages: 1731-1740

10.1111/nmo.12874 | PMID 27283929 Get It

Abstract Background Therapeutic options for management of diabetic gastroparesis are limited. Failure to maintain upregulation of heme oxygenase ( HO 1) leads to loss of interstitial cells of Cajal and delayed gastric emptying ( GE ) in non‐obese diabetic mice. Our hypothesis was that hemin upregulation of HO 1 would restore normal GE in humans with gastroparesis. Aims To compare effects of hemin and placebo infusions on HO 1 activity and protein, GE , autonomic function, and gastrointestinal symptoms in diabetic gastroparesis. Methods In a single‐center, double‐blind, placebo‐controlled, randomized clinical trial, we compared intravenous hemin, prepared in albumin, or albumin alone (placebo) in 20 patients, aged 41 ± 5 ( SEM ) years with diabetic gastroparesis. After infusions on days 1, 3, and 7, weekly infusions were administered for 7 additional weeks. Assessments included blood tests for HO 1 protein and enzyme activity levels, GE with 13 C‐spirulina breath test, autonomic functions (baseline and end), and gastrointestinal symptoms every 2 weeks. Key Results Nine of 11 patients randomized to hemin completed all study procedures. Compared to placebo, hemin increased HO 1 protein on days 3 ( p = 0.0002) and 7 ( p = 0.008) and HO 1 activity on day 3 ( p = 0.0003) but not after. Gastric emptying, autonomic functions, and symptoms did not differ significantly in the hemin group relative to placebo. Conclusions & Inferences Hemin failed to sustain increased HO 1 levels beyond a week and did not improve GE or symptoms in diabetic gastroparesis. Further studies are necessary to ascertain whether more frequent hemin infusions or other drugs would have a more sustained effect on HO 1 and improve GE .
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients
Herrera, Sabrina , Wang, T, Forero, Andres , Nanda, Rita , Pavlick, AC, Fuqua, SAW, Gutiérrez, Carlos , Hilsenbeck, SG, Li, MM, Osborne, CK, Rimawi, MF, Rimawi, Mothaffar F. , Contreras, Alejandro , Mayer, Ingrid A. , Goetz, Matthew P. , Chang, Jae Chan , Fuqua, SAW, Schiff, Rachel , Rimawi, Mothaffar

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 24_Supplement | Pages: PD1-2-PD1-2

10.1158/0008-5472.sabcs13-pd1-2 Get It

Abstract We have recently reported that in patients with HER2-positive breast cancer, neoadjuvant targeted therapy with lapatinib and trastuzumab to more completely block the HER receptor layer, combined with endocrine therapy (in ER-positive tumors) and without chemotherapy led to a substantial 27% pathologic complete response (pCR) rate in the breast. Activation of downstream signaling pathways may lead to resistance to therapies targeting the HER pathway receptors. Aberrant activation of the PI3K pathway via decreased levels of PTEN and/or the presence of activating PIK3CA mutations has been implicated in resistance to targeted anti-HER2 therapy, but results of clinical trials are all confounded by the co-administration of chemotherapy and are inconsistent. We sought to clarify the role of these variables in predicting pCR, a surrogate for long-term outcome, in patients treated with potent targeted therapy alone in a prospective Phase II neoadjuvant trial in patients with HER2-positive breast cancer. Patients with large tumors (median 6 cm) were given 12 weeks of lapatinib plus trastuzumab followed by surgery (Rimawi et al. JCO, 2013). Serial tissue biopsies were obtained from study participants. For this study, we focused on baseline pre-treatment characteristics. PTEN protein levels were measured by IHC and scored using the H-score. PIK3CA mutations were identified on extracted DNA using multiplex PCR with targeted next generation sequencing (the Ion Torrent 50-gene cancer mutation panel). Of 64 evaluable patients, tissue was available on 59 for PTEN IHC, and sufficient DNA was available on 33 for the mutation panel. PTEN median H-score was 100 (range 0-300). PTEN status when dichotomized by the median was correlated with pCR (32% in high PTEN vs. 9% in low PTEN, p = 0.04). Activating PIK3CA mutations were identified in 12 out of 33 tumors (36%; 3 mutations in the helical and 9 in the catalytic domain) and were independent of ER status. None of the patients whose tumors harbored a PIK3CA mutation achieved pCR (p = 0.06). There was no association between PTEN status and PIK3CA mutation suggesting they are independent variables (p = 0.44). When PIK3CA mutations were considered together with PTEN status, there were 31 cases with data on both. The overall pCR rate in this cohort was 16% (lower than pCR rate observed in the overall trial). However, 0/17 cases (0%) with a mutation and/or PTEN low expression (<100 H score) had a pCR compared to 5/14 cases (36%) with PI3KCA wild type and high PTEN levels (p = 0.01). We conclude that PI3K pathway activation downstream of HER2 as a result of either low PTEN or activating PIK3CA mutation results in resistance to the combination of lapatinib and trastuzumab. This is the first report on patient tissue samples from a neoadjuvant trial using the combination of lapatinib and trastuzumab without chemotherapy. If validated in a larger cohort, our findings suggest that patients with HER2 positive tumors and who also harbor aberrant downstream PI3K pathway activation may benefit from the addition of PI3K/Akt/mTOR inhibitors to potent HER2 blockade. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD1-2.
Spontaneous Coronary Artery Dissection
Alfonso, Fernándo , Rivero, Fernando , Cuesta, Javier , Benedicto, Amparo, Saw, Jacqueline , Gulati, Rajiv , Bastante, Teresa

Mayo Clinic

Circulation Journal | August 12, 2014 | Volume: 78 | Issue: 9 | Pages: 2099-2110

10.1253/circj.cj-14-0773 | PMID 25131524 Get It

Effects of aspirin & simvastatin and aspirin, simvastatin, & lipoic acid on heme oxygenase‐1 in healthy human subjects
Bharucha, Adil E. , Choi, Kyoung Moo , Saw, Jessica J. , Gibbons, Simon J. , Farrugia, Gianrico , Carlson, David A. , Zinsmeister, Alan R., Saw, J J , Gibbons, S J

Mayo Clinic

Neurogastroenterology & Motility | July 30, 2014 | Volume: 26 | Issue: 10 | Pages: 1437-1442

10.1111/nmo.12404 | PMID 25093998 Get It

AbstractBackgroundHeme oxygenase 1 (HO‐1) degrades heme and protects against oxidative stress. In vitro and animal models suggest that HO‐1 is beneficial in several diseases (e.g., postoperative ileus, gastroparesis, acute pancreatitis, and colitis). However, the only drugs (i.e., hemin and heme arginate) which pharmacologically upregulate HO‐1 in humans are expensive and can only be administered intravenously. Our aims were to compare the effects of placebo, aspirin, and simvastatin alone, and with α‐lipoic acid, on HO‐1 protein concentration and activity in humans.MethodsThis randomized, double‐blind, placebo‐controlled study compared the effects of three oral regimens administered for 7 days, i.e., placebo; aspirin (325 mg twice daily) and simvastatin (40 mg twice daily); aspirin, simvastatin, and the sodium salt of R‐ α‐lipoic acid (NaRLA, 600 mg three times daily) on markers of HO‐1 activation (i.e., plasma HO‐1 protein concentration and venous monocyte HO‐1 protein activity) in 18 healthy subjects (14 females). Markers of HO‐1 activation were evaluated at baseline, days 2, and 7.Key ResultsBaseline HO‐1 protein concentrations and activity were similar among the three groups. Compared to placebo, aspirin and simvastatin combined, or together with NaRLA did not affect HO‐1 protein concentration or activity at 2 or 7 days. HO‐1 protein concentrations and activity were correlated on day 7 (r = 0.75, p = 0.0004) but not at baseline and on day 2.Conclusions & InferencesAt therapeutic doses, aspirin, simvastatin, and α‐lipoic acid do not increase plasma HO‐1 protein concentration or venous monocyte HO‐1 activity in healthy humans.
Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial
Saw, Jacqueline , Steinhubl, Steven R., Berger, Peter B. , Kereiakes, Dean J. , Serebruany, Victor L. , Brennan, Danielle M., Topol, Eric J.

Mayo Clinic

Circulation | August 18, 2003 | Volume: 108 | Issue: 8 | Pages: 921-924

10.1161/01.cir.0000088780.57432.43 | PMID 12925453 Get It

Background— Statins primarily metabolized by cytochrome P450 3A4 (CYP3A4) reportedly reduce clopidogrel’s metabolism to active metabolite, thus attenuating its inhibition of platelet aggregation ex vivo. However, the clinical impact of this interaction has not been evaluated. Methods and Results— Clopidogrel for the Reduction of Events During Observation (CREDO) was a double-blind, placebo-controlled, randomized trial comparing pretreatment (300 mg) and 1-year (75 mg/d) clopidogrel therapy (clopidogrel) with no pretreatment and 1-month clopidogrel therapy (75 mg/d) (control) after a planned percutaneous coronary intervention. All patients received aspirin. The 1-year primary end point was a composite of death, myocardial infarction, and stroke. We performed a post hoc analysis to evaluate the clinical efficacy of concomitant clopidogrel and statin administration, categorizing baseline statin use to those predominantly CYP3A4-metabolized (atorvastatin, lovastatin, simvastatin, and cerivastatin) (CYP3A4-MET) or others (pravastatin and fluvastatin) (non-CYP3A4-MET). Of the 2116 patients enrolled, 1001 received a CYP3A4-MET and 158 a non-CYP3A4-MET statin. For the overall study population, the primary end point was significantly reduced in the clopidogrel group (8.5% versus 11.5%, RRR 26.9%; P =0.025). This clopidogrel benefit was similar with statin use, irrespective of treatment with a CYP3A4-MET (7.6% clopidogrel, 11.8% control, RRR 36.4%, 95% CI 3.9 to 57.9; P =0.03) or non-CYP3A4-MET statin (5.4% clopidogrel, 13.6% control, RRR 60.6%, 95% CI −23.9 to 87.4; P =0.11). Patients given atorvastatin or pravastatin had similar 1-year event rates. Additionally, concomitant therapy with statins had no impact on major or minor bleeding rates. Conclusions— Although ex vivo testing has suggested a potential negative interaction when coadministering a CYP3A4-metabolized statin with clopidogrel, this was not clinically observed statistically in a post hoc analysis of a placebo-controlled study.